Abstract
Serum tetranectin (Se-TN) and CA-125 were measured in serum samples obtained before primary surgery, before start of chemotherapy and monthly during chemotherapy in 8 patients with ovarian cancer. The median Se-TN level before chemotherapy (7.3 mg/l) increased significantly after the start of chemotherapy (13.7 mg/l), with the highest increase for one survivor (145%). Five patients who died of cancer in the study period, had pronounced decreases (30-50%) in Se-TN with a maximal concentration during chemotherapy to the lowest concentration in the last sample. One patient who died 10 months after closure of the study had continuously normal Se-TN values, but the last CA-125 value elevated. The lead time could be calculated in four patients for Se-TN and six patients for CA-125. Median lead times of 3.6 months and 3.8 months were found for Se-TN and CA-125 respectively. In conclusion, chemotherapy induces significant increases in Se-TN levels. A decrease in Se-TN during chemotherapy is highly suspect for recurrence and a poor outcome. Measurements of TN should therefore be included in other comparative studies.
| Original language | English |
|---|---|
| Journal | European journal of obstetrics, gynecology, and reproductive biology |
| Volume | 57 |
| Issue number | 3 |
| Pages (from-to) | 175-8 |
| Number of pages | 4 |
| ISSN | 0301-2115 |
| DOIs | |
| Publication status | Published - Dec 1994 |
| Externally published | Yes |
Keywords
- Aged
- Biomarkers, Tumor/blood
- Blood Proteins/analysis
- CA-125 Antigen/blood
- Combined Modality Therapy
- Drug Monitoring
- Female
- Follow-Up Studies
- Humans
- Lectins, C-Type
- Middle Aged
- Neoplasm Recurrence, Local/blood
- Ovarian Neoplasms/blood
- Survival Rate
- Time Factors
Fingerprint
Dive into the research topics of 'Serum tetranectin and CA-125 used to monitor the course of treatment in ovarian cancer patients'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS